

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-8 (Cancelled)

Claim 9 (Currently Amended) A method for inhibiting synovial cell growth, comprising administering to a patient in need thereof a pharmaceutical composition comprising humanized PM-1 antibody and a physiologically acceptable carrier, wherein said humanized PM-1 antibody comprises  
(A) L chains of an antibody to a human IL-6 receptor, each comprising:  
(1) a variable (V) region of a light (L) chain of an antibody to the human IL-6 receptor having the following structure:  
FR1<sup>1</sup>-CDR1<sup>1</sup>-FR2<sup>1</sup>-CDR2<sup>1</sup>-FR3<sup>1</sup>-CDR3<sup>1</sup>-FR4<sup>1</sup>  
wherein CDR1<sup>1</sup>, CDR2<sup>1</sup> and CDR3<sup>1</sup> represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:

CDR1<sup>1</sup> Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn (SEQ ID NO: 2)

CDR2<sup>1</sup> Tyr Thr Ser Arg Leu His Ser (SEQ ID NO: 3)

CDR3<sup>1</sup> Gln Gln Gly Asn Thr Leu Pro Tyr Thr (SEQ ID NO: 4);  
and the FR1<sup>1</sup>, FR2<sup>1</sup>, FR3<sup>1</sup> and FR4<sup>1</sup> comprise a set of the following amino acid sequences:

FR1<sup>1</sup> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID NO: 5)

FR2<sup>1</sup> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu  
Ile Tyr (SEQ ID NO: 6)

FR3<sup>1</sup> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr  
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp  
Ile Ala Thr Tyr Tyr Cys (SEQ ID NO: 7)

FR4<sup>1</sup> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO: 8);

or

FR1<sup>1</sup> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID NO:  
5)

FR2<sup>1</sup> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu  
Ile Tyr (SEQ ID NO: 6)

FR3<sup>1</sup> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr  
Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp  
Ile Ala Thr Tyr Tyr Cys (SEQ ID NO: 9)

FR4<sup>1</sup> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO:  
8);

and

(2) a C region of an L chain of a human antibody Cκ; and

(B) H chains of an antibody to the human IL-6 receptor, each comprising:

(1) a V region of a heavy (H) chain of an antibody to the human IL-6  
receptor having the following structure:

FR1<sup>2</sup>-CDR1<sup>2</sup>-FR2<sup>2</sup>-CDR2<sup>2</sup>-FR3<sup>2</sup>-CDR3<sup>2</sup>-FR4<sup>2</sup>

wherein CDR1<sup>2</sup>, CDR2<sup>2</sup> and CDR3<sup>2</sup> represent a set of three  
complementarity determining regions comprising a set of the following  
amino acid sequences:

CDR1<sup>2</sup> Ser Asp His Ala Trp Ser (SEQ ID NO: 10)

CDR2<sup>2</sup> Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser  
Leu Lys Ser (SEQ ID NO: 11)

CDR3<sup>2</sup> Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr (SEQ ID  
NO: 12);

and the FR1<sup>2</sup>, FR2<sup>2</sup>, FR3<sup>2</sup> and FR4<sup>2</sup> comprise a set of the following  
amino acid sequences:

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Ser Ile Thr (SEQ ID NO: 13)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

FR1<sup>2</sup> Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr (SEQ ID NO: 17)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met Gly (SEQ ID NO: 18)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met Gly (SEQ ID NO: 18)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

FR1<sup>2</sup> Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr (SEQ ID NO: 17)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

or

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Val Asp Thr Ser Lys Asn Gln Phe  
Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala  
Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 20)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

and

(2) a C region of an H chain of a human antibody Cy.

Claim 10 (Cancelled)

Claim 11 (Previously Presented) The method according to claim 9, wherein the patient is a human.

Claim 12 (Previously Presented) The method according to claim 11, wherein the antibody is administered in four divided doses from about 1 to 1000 mg.

Claim 13 (Currently Amended) A method of treating chronic rheumatoid arthritis, comprising administering to a patient in need thereof a pharmaceutical

composition comprising humanized PM-1 antibody and a physiologically acceptable carrier, wherein said humanized PM-1 antibody comprises

(A) L chains of an antibody to a human IL-6 receptor, each comprising:

(1) a variable (V) region of a light (L) chain of an antibody to the human IL-6 receptor having the following structure:

FR1<sup>1</sup>-CDR1<sup>1</sup>-FR2<sup>1</sup>-CDR2<sup>1</sup>-FR3<sup>1</sup>-CDR3<sup>1</sup>-FR4<sup>1</sup>

wherein CDR1<sup>1</sup>, CDR2<sup>1</sup> and CDR3<sup>1</sup> represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:

CDR1<sup>1</sup> Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn (SEQ ID NO: 2)

CDR2<sup>1</sup> Tyr Thr Ser Arg Leu His Ser (SEQ ID NO: 3)

CDR3<sup>1</sup> Gln Gln Gly Asn Thr Leu Pro Tyr Thr (SEQ ID NO: 4);  
and the FR1<sup>1</sup>, FR2<sup>1</sup>, FR3<sup>1</sup> and FR4<sup>1</sup> comprise a set of the following amino acid sequences:

FR1<sup>1</sup> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID NO: 5)

FR2<sup>1</sup> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu  
Ile Tyr (SEQ ID NO: 6)

FR3<sup>1</sup> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr  
Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp  
Ile Ala Thr Tyr Tyr Cys (SEQ ID NO: 7)

FR4<sup>1</sup> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO: 8);

or

FR1<sup>1</sup> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
Ser Val Gly Asp Arg Val Thr Ile Thr Cys (SEQ ID NO: 5)

FR2<sup>1</sup> Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu  
Ile Tyr (SEQ ID NO: 6)

FR3<sup>1</sup> Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr  
Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp  
Ile Ala Thr Tyr Tyr Cys (SEQ ID NO: 9)

FR4<sup>1</sup> Phe Gly Gln Gly Thr Lys Val Glu Ile Lys (SEQ ID NO: 8);

and

(2) a C region of an L chain of a human antibody Cκ; and

(B) H chains of an antibody to the human IL-6 receptor, each comprising:

(1) a V region of a heavy (H) chain of an antibody to the human IL-6 receptor having the following structure:

FR1<sup>2</sup>-CDR1<sup>2</sup>-FR2<sup>2</sup>-CDR2<sup>2</sup>-FR3<sup>2</sup>-CDR3<sup>2</sup>-FR4<sup>2</sup>

wherein CDR1<sup>2</sup>, CDR2<sup>2</sup> and CDR3<sup>2</sup> represent a set of three complementarity determining regions comprising a set of the following amino acid sequences:

CDR1<sup>2</sup> Ser Asp His Ala Trp Ser (SEQ ID NO: 10)

CDR2<sup>2</sup> Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser  
Leu Lys Ser (SEQ ID NO: 11)

CDR3<sup>2</sup> Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr (SEQ ID  
NO: 12);

and the FR1<sup>2</sup>, FR2<sup>2</sup>, FR3<sup>2</sup> and FR4<sup>2</sup> comprise a set of the following amino acid sequences:

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Ser Ile Thr (SEQ ID NO: 13)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 17)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met  
Gly (SEQ ID NO: 18)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met  
Gly (SEQ ID NO: 18)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 17)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID  
NO: 16);

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg  
Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  
Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile  
Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln  
Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr  
Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 15)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

or

FR1<sup>2</sup> Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr (SEQ ID NO: 19)

FR2<sup>2</sup> Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly (SEQ ID NO: 14)

FR3<sup>2</sup> Arg Val Thr Met Leu Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg (SEQ ID NO: 20)

FR4<sup>2</sup> Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser (SEQ ID NO: 16);

and

(2) a C region of an H chain of a human antibody Cy.

Claim 14 (Previously Presented) The method according to claim 13, wherein the antibody suppresses abnormal growth of synovial cells.

Claim 15 (Cancelled)

Claim 16 (Previously Presented) The method according to claim 13, wherein the patient is a human.

Claim 17 (Previously Presented) The method according to claim 16, wherein the antibody is administered in four divided doses from about 1 to 1000 mg.

Claim 18 (Cancelled)